BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33753628)

  • 21. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC; Grebe SK
    Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutations in the parental tumour accelerate in vitro growth of tumoroids established from colorectal adenocarcinoma.
    Mousavi N; Truelsen SLB; Hagel G; Jorgensen LN; Harling H; Timmermans V; Melchior LC; Thysen AH; Heegaard S; Thastrup J
    Int J Exp Pathol; 2019 Feb; 100(1):12-18. PubMed ID: 30884019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.
    Chen CL; Chen CK; Ho CL; Chi WM; Yeh CH; Hu SP; Friebe P; Palmer S; Huang CS
    Mol Diagn Ther; 2019 Oct; 23(5):645-656. PubMed ID: 31347028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
    Mack E; Stabla K; Riera-Knorrenschild J; Moll R; Neubauer A; Brendel C
    BMC Cancer; 2016 Aug; 16():585. PubMed ID: 27485514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers-a Study from Indian Regional Cancer Centre.
    Smitha CS; Suresh BMC; Linu JA; Lakshmaiah KC; Govind BK; Lokanatha D; Pretesh RK
    Indian J Surg Oncol; 2017 Dec; 8(4):511-513. PubMed ID: 29203982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports.
    Macedo MP; Andrade Lde B; Coudry R; Crespo R; Gomes M; Lisboa BC; Aguiar S; Soares FA; Carraro DM; Cunha IW
    Int J Colorectal Dis; 2011 Oct; 26(10):1241-8. PubMed ID: 21603900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography.
    Karim B; Florence C; Kamel R; Nadia K; Ines O; Raja M; Sarra BJ; Florent S; Amel BA
    Cancer Biomark; 2010-2011; 8(6):331-40. PubMed ID: 22072121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driver Gene Mutations in Stools of Colorectal Carcinoma Patients Detected by Targeted Next-Generation Sequencing.
    Armengol G; Sarhadi VK; Ghanbari R; Doghaei-Moghaddam M; Ansari R; Sotoudeh M; Puolakkainen P; Kokkola A; Malekzadeh R; Knuutila S
    J Mol Diagn; 2016 Jul; 18(4):471-9. PubMed ID: 27155048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
    Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
    Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.